Researchers at Oxford University said on Thursday that the risk of developing rare blood clots is higher after being infected with COVID-19 than in vaccinated people.
The findings come in a new study published by the university, which helped develop the AstraZeneca vaccine which has now been scrutinized for possible links to a blood clot in the brain known as cerebral venous sinus thrombosis (CVST).
After comparing the number of cases of CVST in the two weeks following the diagnosis of COVID-19 and after the first dose of vaccine, Oxford reports that the risk of developing blood clots is up to 10 times higher after an infection. by COVID-19 which is after a vaccination.
The researchers noted that, compared to Pfizer and Moderna vaccines, the risk of developing CVST is about 10 times higher, while the risk is about eight times higher compared to Oxford-AstraZeneca inoculation.
Although the study noted that data on possible links between vaccines and blood clots are still under review, Paul Harrison, head of the Oxford group of translational neurobiology, said Thursday’s findings they must be taken into account when considering the balances between the risks and benefits of vaccination. ”
The study comes after a wave of countries limited the use of the AstraZeneca vaccine to older age groups due to reports of blood clots.
On Wednesday, Denmark became the first European country stop completely the use of the AstraZeneca trait after an investigation “It showed real and serious side effects,” according to the Danish health authority.
A European Medicines Agency (EMA) safety committee he said last week that there is a “possible link” between the AstraZeneca vaccine and blood clots, although he added that the benefits of inoculation to protect against COVID-19 outweigh the risks.
The Oxford study did not include data on the shooting of Johnson & Johnson, which has been arrested in the US on the recommendation of health authorities reviewing six cases of blood clots among the 7 million people who received the shot .
An independent advisory group from the Centers for Disease Control and Prevention on Wednesday postponed the filing of a recommendation on Johnson & Johnson’s shot until further testing on blood clots, likely extending the distribution of one of three vaccines against federally approved coronavirus for emergency use The US